{"schema_version":"secwatch.filing_event.v1","accession":"0001636282-23-000016","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.890165+00:00","generated_at":"2026-06-08T06:49:41.827032+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aeglea BioTherapeutics Q3 2023 net loss $40.1M; cash $204.9M; IBD pipeline on track","bullets":["Net loss $40.1M in Q3 2023 vs $18.2M a year ago, reflecting $24.7M R&D (+106% YoY) and $21.8M other expense.","Cash, equivalents, marketable securities and restricted cash $204.9M at Sept 30, 2023, expected runway into 2026.","SPY001 anti-α4β7 IND expected H1 2024; healthy volunteer interim data year-end 2024.","SPY002 anti-TL1A IND expected H2 2024; picomolar affinity for monomer/trimer cited.","Stockholder vote Nov 21 to authorize preferred-to-common conversion; sold pegzilarginase to Immedica for $15M upfront plus milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-23-000016","json":"https://secwatch.observer/filing/0001636282-23-000016.json","markdown":"https://secwatch.observer/filing/0001636282-23-000016.md","text":"https://secwatch.observer/filing/0001636282-23-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628223000016/0001636282-23-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628223000016/agle-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:49:41.827032+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12be94a99408fc6779b8b6b07c7635ea0759e0bc","claim":"Spyre Therapeutics, Inc. reported financial results for third quarter 2023.","evidence_excerpt":"On November 9, 2023, Aeglea BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628223000016/0001636282-23-000016-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}